PITTSBURGH – PANTHERx Rare, the six-time winner of the Annual MMIT Patient Choice Award, once again, has the TOP Net Promoter Score for all independent specialty pharmacies in America for the Third Quarter of 2023 – the third top score this year.

MMIT is an independent national survey entity that asks patients how likely they would be to recommend their specialty pharmacy to a friend or family member. The critical feedback afforded by the MMIT Patient Satisfaction survey allows PANTHERx to measure success and adjust programs to the needs and desires of the patients served. Feedback received via the survey highlighted things like exceptional customer service in several areas and professionalism of the staff.

“PANTHERx was founded on the mission to serve people living with rare and devastating conditions. The continued commitment of PANTHERx’s associates to care for each person’s health journey through compassion, empathy, education, training, and innovative technology is validated by those individuals who we serve. PANTHERx consistently scores in the mid- to uppers-90s on our NPS score, which is unheard of in the independent specialty pharmacy market,” said PANTHERx Rare Chief Executive Officer Rob Snyder.

PANTHERx Rare is the leader in rare disease pharmacy in the United States, transforming the lives of individuals with rare and devastating conditions by delivering medicine breakthroughs, clinical excellence, and access to vital care solutions. PANTHERx is focused on medications that have Orphan designation by the FDA and where the manufacturer chooses an exclusive or highly limited specialty pharmacy distribution strategy. As the six (6) time winner of MMIT’s Patient Choice Award, PANTHERx has proven superior customer satisfaction through RxARECARE programs working with patients through their personal journey.

PANTHERx is headquartered in Pittsburgh, serving patients and providers in all 50 states and U.S. territories, with accreditations from URAC (including Rare Disease Designation), NABP, and ACHC (including Rare Disease Distinction).